Overview

• US biotechnology firm's Q1 net loss widened slightly as operating expenses increased

• Cash and cash equivalents rose to $13.7 ml

Outlook

• Company expects data from Phase 1 Part 3 DA-1726 obesity trial in Q4 2026

• MetaVia expects cash position to fund operations into Q4 2026

Result Drivers

• R&D EXPENSES - Q1 R&D expenses fell $0.2 mln, mainly due to lower direct costs for vanoglipel development and reduced employee compensation

• G&A EXPENSES - Q1 G&A expenses rose $0.3 mln, mainly due to higher consulting, franchise tax, and legal/professional fees

Company press release: ID:nPnbrmSBRa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Net Income		-$3.82 mln
Q1 Income from Operations		-$4.03 mln
Q1 Operating Expenses		$4.03 mln
Q1 Pretax Profit		-$3.82 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for MetaVia Inc is $20.00, about 1,566.7% above its May 13 closing price of $1.20

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.